MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$13,000K
Proceeds from issuance of
common stock in...
$2,560K
Cash provided by
financing activities
$13,390K
Canceled cashflow
$2,170K
Net increase in cash
and cash...
$3,201K
Canceled cashflow
$10,189K
Payment of deferred
stock issuance costs
$2,169K
Payment for fractional
shares in connection...
$1K
Stock-based compensation
expense
$793K
Accounts payable
$663K
Prepaid expenses and
other current assets
-$251K
Accrued expenses
$59K
Change in operating
lease right of use...
$48K
Depreciation expense
$4K
Cash used in
operating activities
-$10,186K
Cash used in
investing activities
-$3K
Canceled cashflow
$1,818K
Net loss
-$11,956K
Purchase of property and
equipment
$3K
Operating lease
liabilities
-$48K
Back
Back
Cash Flow
source: myfinsight.com
GRI Bio, Inc. (GRI)
GRI Bio, Inc. (GRI)